Marinomed Biotech AG (WBO:MARI) Total Liabilities : €24.75 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Marinomed Biotech AG Total Liabilities?

Marinomed Biotech AG's Total Liabilities for the quarter that ended in Dec. 2023 was €24.75 Mil.

Marinomed Biotech AG's quarterly Total Liabilities declined from Jun. 2023 (€24.85 Mil) to Sep. 2023 (€24.29 Mil) but then increased from Sep. 2023 (€24.29 Mil) to Dec. 2023 (€24.75 Mil).

Marinomed Biotech AG's annual Total Liabilities increased from Dec. 2021 (€21.15 Mil) to Dec. 2022 (€26.44 Mil) but then declined from Dec. 2022 (€26.44 Mil) to Dec. 2023 (€24.75 Mil).

Marinomed Biotech AG Total Liabilities Historical Data

The historical data trend for Marinomed Biotech AG's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marinomed Biotech AG Total Liabilities Chart

Marinomed Biotech AG Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

8.64

18.14

21.15

26.44

24.75

Marinomed Biotech AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															26.44	25.04	24.85	24.29	24.75

Marinomed Biotech AG Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Marinomed Biotech AG's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	9.653	+	(14.84	+	0.255
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	24.75

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	14.612	-	-10.136
	=	24.75

Marinomed Biotech AG's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	9.653	+	(14.84	+	0.255
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	24.75

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	14.612	-	-10.136
	=	24.75

Marinomed Biotech AG Total Liabilities Related Terms

Thank you for viewing the detailed overview of Marinomed Biotech AG's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Marinomed Biotech AG (WBO:MARI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marinomed Biotech AG (WBO:MARI) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

93Z:Germany

Address

Hovengasse 25, Korneuburg, AUT, 2100

Website

https://www.marinomed.com

Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The products marketed by the company are based on its platform Carragelose and Marinosolv. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generates from the virology segment.

Marinomed Biotech AG (WBO:MARI) Headlines

No Headlines